# Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.

> **NCT02017444** · PHASE2 · COMPLETED · sponsor: **University of Birmingham** · enrollment: 31 (actual)

## Conditions studied

- Idiopathic Intracranial Hypertension

## Interventions

- **DRUG:** AZD4017
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02017444
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-25
- **Primary completion:** 2016-12-19
- **Final completion:** 2016-12-19
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017444, "Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02017444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*